Esperion Therapeutis.Inc. buy Heureka
Summary
This prediction ended on 09.03.20 with a price of €39.12. Massive losses of -30.14% were the result for the BUY prediction by Heureka. Heureka has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | -26.389% | -26.389% | 67.455% | -88.983% |
iShares Core DAX® | 1.080% | -2.131% | 14.264% | 15.290% |
iShares Nasdaq 100 | 0.362% | 7.059% | 35.383% | 56.103% |
iShares Nikkei 225® | -1.155% | -0.483% | 8.258% | 4.324% |
iShares S&P 500 | 0.806% | 5.037% | 29.635% | 49.529% |
Comments by Heureka for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Heureka for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
13.01.20
10.02.20
10.02.20